Kick, Anastas http://orcid.org/0009-0001-8132-8299
M’Rabet-Bensalah, Khadija http://orcid.org/0009-0001-5794-2184
Acquistapace, Flavio
Amadid, Hanan http://orcid.org/0000-0001-5759-4960
Ambühl, Robert A.
Braae, Uffe Christian http://orcid.org/0000-0002-2743-4584
Item, Flurin http://orcid.org/0009-0007-2412-2757
Schultes, Bernd http://orcid.org/0000-0002-5301-1163
Züger, Thomas http://orcid.org/0000-0001-6190-7405
Rudofsky, Gottfried http://orcid.org/0000-0002-2576-7190
Clinical trials referenced in this document:
Documents that mention this clinical trial
Real-World Use of Oral Semaglutide in Adults with Type 2 Diabetes: The PIONEER REAL Switzerland Multicentre, Prospective, Observational Study
https://doi.org/10.1007/s13300-023-01525-y
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 7 November 2023
Accepted: 14 December 2023
First Online: 19 January 2024
Declarations
:
: Anastas Kick: no conflicts to disclose. Flavio Acquistapace: no conflicts to disclose. Robert A. Ambühl: no conflicts to disclose. Bernd Schultes: Bernd Schultes has received presentation fees from and compensation as a member of a scientific advisory board of Novo Nordisk and Eli Lilly, as well as for serving as a study investigator for Novo Nordisk. Thomas Züger: no conflicts to disclose. Gottfried Rudofsky: no conflicts to disclose. Khadija M'Rabet-Bensalah, Hanan Amadid, Flurin Item and Uffe Christian Braae are employees of and shareholders in Novo Nordisk.
: The study protocol was approved by the appropriate health authorities according to local guidelines and by an Institutional Review Board/Independent Ethics Committee. The Ethics Committees included: Ethikkommission der Nordwest-und Zentralschweiz (EKNZ), Ethikkommission Zurich, Ethikkommission Ostschweiz (EKOS), Kantonale Ethikkommission Bern (KEK-Bern) and Commission cantonale (VD) d'éthique de la recherche sur l'être humain, Comitato etico cantonale Ticino. The study was conducted in accordance with the Declaration of Helsinki and International Council on Harmonisation Good Clinical Practice guidelines. Participants provided written informed consent prior to commencement of any study-related activity. The study is registered with ClinicalTrials.gov (NCT04537624).